A single dose bioavailability study of 3 new formulations of SKI-606 [bosutinib] (500 mg) compared with a reference capsule and an oral solution in healthy adult subjects

Trial Profile

A single dose bioavailability study of 3 new formulations of SKI-606 [bosutinib] (500 mg) compared with a reference capsule and an oral solution in healthy adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2007

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Breast cancer; Chronic myeloid leukaemia; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 26 Dec 2007 Status change from in progress to completed.
    • 11 Sep 2007 Status changed from initiated to in progress.
    • 07 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top